Unresectable Thyroid Cancer
Conditions
Interventions
Conversion surgery is performed for local control if the tumor is resectable after molecular targeted therapy approved in Japan (i.e., Selpercatinib, Lenvatinib, Sorafenib, or dabrafenib/trametinib).
Sponsors
Ito Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Pathologic findings supporting papillary thyroid carcinoma, follicular thyroid carcinoma, poorly differentiated carcinoma, or medullary thyroid carcinoma 2) The tumor was considered to be unresectable by CT scan and/or palpation 3) Regardless of distant metastasis/nonregional lymph node metastasis status 4) At least 12 years of age on the day of signing an informed consent 5) Willing and able to provide written informed consent signed by the study patient (or legally acceptable representative if applicable)
Exclusion criteria
Exclusion criteria: 1) Recurrent case 2) The cases with tumor invasion reaching into tracheal/esophageal/laryngeal/ pharyngeal lumen (i.e., the superficial layers of these organs) or large vessels. 3) Having any contraindications for all molecularly targeted drugs planned to use. 4) Patients unable to withstand surgery. 5) Psychiatric disease 6) Eastern Cooperative Oncology Group performance status (PS) of 3 or 4 7) Pregnancy or lactation 8) Any other cases that are regarded as inadequate for study enrollment by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of conversion surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of local resection (R0/1/2), Locoregional progression-free survival, Overall survival, Progression-free survival, Treatment-related death, Perioperative complications, and Combined resection of other organs. | — |
Countries
Japan
Contacts
Public ContactSaito Yoshiyuki
Ito Hospital Department of Surgery
Outcome results
None listed